Owkin

Owkin is an AI biotech company that uses federated learning to train AI models across distributed hospital and research datasets without centralizing patient data. The company's platform enables precision oncology by discovering predictive biomarkers and optimizing clinical trial design. Owkin achieved unicorn status through a $180M strategic investment from Sanofi and led the MELLODDY consortium, the first federated learning platform for drug discovery involving 10 pharmaceutical companies.

Federated learning platform that trains AI models across decentralized hospital datasets without pooling patient data. This privacy-preserving approach enables access to diverse, real-world clinical data for biomarker discovery, patient stratification, and clinical trial optimization in oncology.